Adoptive T-cell Immunotherapy: Perfecting Self-Defenses

Raphaëlle Toledano Zur, Galit Adler, Katerina Shamalov, Yair Tal, Chen Ankri, Cyrille J. Cohen

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


As an important part of the immune system, T lymphocytes exhibit undoubtedly an important role in targeting and eradicating cancer. However, despite these characteristics, their natural antitumor response may be insufficient. Numerous clinical trials in terminally ill cancer patients testing the design of novel and efficient immunotherapeutic approaches based on the adoptive transfer of autologous tumor-specific T lymphocytes have shown encouraging results. Moreover, this also led to the approval of engineered T-cell therapies in patients. Herein, we will expand on the development and the use of such strategies using tumor-infiltrating lymphocytes or genetically engineered T-cells. We will also comment on the requirements and potential hurdles encountered when elaborating and implementing such treatments as well as the exciting prospects for this kind of emerging personalized medicine therapy.

Original languageEnglish
Title of host publicationExperientia supplementum (2012)
PublisherSpringer Basel
Number of pages42
StatePublished - 2022

Publication series

NameExperientia supplementum (2012)
ISSN (Print)1664-431X
ISSN (Electronic)2504-3692

Bibliographical note

Publisher Copyright:
© 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.


  • Adoptive Cell Therapy
  • CAR-T-cells
  • Cancer
  • T-cell Receptor
  • T-cells engineering
  • Tumor-Infiltrating Lymphocytes


Dive into the research topics of 'Adoptive T-cell Immunotherapy: Perfecting Self-Defenses'. Together they form a unique fingerprint.

Cite this